Investors Target Embecta in Class Action Following 57% Stock Plunge

The complaint filed by Robbins LLP centers on the period between November 25, 2025, and May 4, 2026. During this window, plaintiffs allege that Embecta executives consistently reaffirmed revenue guidance while concealing material weaknesses in their core pen needle segment. The firm claims these statements were materially false, artificially inflating stock prices before the market reality set in.

The fallout arrived on May 5, 2026, when the company revealed it had missed second-quarter targets and subsequently reduced its full-year guidance by 46%. Alongside the revenue warning, Embecta slashed its dividend by 93%. The market reaction was immediate, with shares falling more than 57% to close at $3.90. Investors who purchased stock during the class period are now being encouraged to evaluate their eligibility for the litigation, with a deadline of August 17, 2026, for those seeking to serve as lead plaintiff.